osteitis deformans

Summary

Summary: A disease marked by repeated episodes of increased bone resorption followed by excessive attempts at repair, resulting in weakened, deformed bones of increased mass. The resultant architecture of the bone assumes a mosaic pattern in which the fibers take on a haphazard pattern instead of the normal parallel symmetry.

Top Publications

  1. ncbi Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein
    Giles D J Watts
    Division of Genetics, Children s Hospital Boston, 300 Longwood Avenue, Harvard Medical School, Boston, Massachusetts 02115, USA
    Nat Genet 36:377-81. 2004
  2. ncbi Valosin containing protein associated inclusion body myopathy: abnormal vacuolization, autophagy and cell fusion in myoblasts
    Jouni Vesa
    Department of Pediatrics, Division of Genetics and Metabolism, University of California, Irvine, CA 92868, USA
    Neuromuscul Disord 19:766-72. 2009
  3. ncbi VCP disease associated with myopathy, Paget disease of bone and frontotemporal dementia: review of a unique disorder
    Virginia E Kimonis
    Division of Genetics and Metabolism, Department of Pediatrics, University of California, Irvine, 101 The City Drive, ZOT 4482, Orange, CA 92868, USA
    Biochim Biophys Acta 1782:744-8. 2008
  4. ncbi Paget disease of bone
    Tim Cundy
    Department of Medicine, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand
    Trends Endocrinol Metab 19:246-53. 2008
  5. ncbi Recent advances in understanding the molecular basis of Paget disease of bone
    A Goode
    School of Biomedical Sciences, University of Nottingham Medical School, Queen s Medical Centre, Nottingham NG7 2UH, UK
    J Clin Pathol 63:199-203. 2010
  6. ncbi Valosin-containing protein (VCP) is required for autophagy and is disrupted in VCP disease
    Jeong Sun Ju
    Department of Neurology, Washington University School of Medicine, St Louis, MO 63110, USA
    J Cell Biol 187:875-88. 2009
  7. ncbi Mutation of the sequestosome 1 (p62) gene increases osteoclastogenesis but does not induce Paget disease
    Noriyoshi Kurihara
    VA Pittsburgh Healthcare System, Research and Development, Pittsburgh, Pennsylvania 15240, USA
    J Clin Invest 117:133-42. 2007
  8. ncbi Differential gene expression in cultured osteoblasts and bone marrow stromal cells from patients with Paget's disease of bone
    Dorit Naot
    Department of Medicine, University of Auckland, New Zealand
    J Bone Miner Res 22:298-309. 2007
  9. ncbi Randomized trial of intensive bisphosphonate treatment versus symptomatic management in Paget's disease of bone
    Anne L Langston
    Rheumatic Diseases Unit, Institute of Genetics and Molecular Medicine University of Edinburgh, United Kingdom
    J Bone Miner Res 25:20-31. 2010
  10. ncbi Genome-wide association study identifies variants at CSF1, OPTN and TNFRSF11A as genetic risk factors for Paget's disease of bone
    Omar M E Albagha
    Rheumatic Diseases Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Edinburgh, UK
    Nat Genet 42:520-4. 2010

Research Grants

  1. CLONING NOVEL GENES FOR PAGETS DISEASE AND OSTEOSARCOMA
    Marc Hansen; Fiscal Year: 2001
  2. TWO X-LINKED GENES THAT REGULATE MINERAL HOMEOSTASIS
    Michael Whyte; Fiscal Year: 2002
  3. AAA ATPase p97/VCP and Inclusion Body Myopathy
    CONRAD WEIHL; Fiscal Year: 2007
  4. IBMPFD MUTATIONS IMPAIR UPS FUNCTION
    Conrad C Weihl; Fiscal Year: 2010
  5. IBMPFD MUTATIONS IMPAIR UPS FUNCTION
    CONRAD WEIHL; Fiscal Year: 2009
  6. IBMPFD MUTATIONS IMPAIR UPS FUNCTION
    CONRAD WEIHL; Fiscal Year: 2009
  7. INHIBITION OF OSTEOCLAST ACTIVITY BY OIP1/HSCAL
    SAKAMURI REDDY; Fiscal Year: 2002
  8. GENE CAUSING PAGET & LIMB-GIRDLE MUSCULAR DYSTROPHY
    Virginia Kimonis; Fiscal Year: 2003
  9. Genetic basis of myopathy with Paget disease of bone
    Virginia Kimonis; Fiscal Year: 2007
  10. Characterization of Familial Myopathy & Paget Disease
    Virginia Kimonis; Fiscal Year: 2005

Detail Information

Publications179 found, 100 shown here

  1. ncbi Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein
    Giles D J Watts
    Division of Genetics, Children s Hospital Boston, 300 Longwood Avenue, Harvard Medical School, Boston, Massachusetts 02115, USA
    Nat Genet 36:377-81. 2004
    ..Identification of VCP as causing IBMPFD has important implications for other inclusion-body diseases, including myopathies, dementias and Paget disease of bone (PDB), as it may define a new common pathological ubiquitin-based pathway...
  2. ncbi Valosin containing protein associated inclusion body myopathy: abnormal vacuolization, autophagy and cell fusion in myoblasts
    Jouni Vesa
    Department of Pediatrics, Division of Genetics and Metabolism, University of California, Irvine, CA 92868, USA
    Neuromuscul Disord 19:766-72. 2009
    ....
  3. ncbi VCP disease associated with myopathy, Paget disease of bone and frontotemporal dementia: review of a unique disorder
    Virginia E Kimonis
    Division of Genetics and Metabolism, Department of Pediatrics, University of California, Irvine, 101 The City Drive, ZOT 4482, Orange, CA 92868, USA
    Biochim Biophys Acta 1782:744-8. 2008
    ..Inclusions seen in the muscle, brain and heart in VCP disease contain ubiquitin, beta amyloid and TDP-43, also seen in other neurodegenerative disorders thus implicating common pathways in their pathogenesis...
  4. ncbi Paget disease of bone
    Tim Cundy
    Department of Medicine, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand
    Trends Endocrinol Metab 19:246-53. 2008
    ..Most observations seem to fit best with the idea that Paget disease behaves as a multifocal benign neoplasm...
  5. ncbi Recent advances in understanding the molecular basis of Paget disease of bone
    A Goode
    School of Biomedical Sciences, University of Nottingham Medical School, Queen s Medical Centre, Nottingham NG7 2UH, UK
    J Clin Pathol 63:199-203. 2010
    ....
  6. ncbi Valosin-containing protein (VCP) is required for autophagy and is disrupted in VCP disease
    Jeong Sun Ju
    Department of Neurology, Washington University School of Medicine, St Louis, MO 63110, USA
    J Cell Biol 187:875-88. 2009
    ..These data implicate VCP in autophagy and suggest that impaired autophagy explains the pathology seen in IBMPFD muscle, including TDP-43 accumulation...
  7. ncbi Mutation of the sequestosome 1 (p62) gene increases osteoclastogenesis but does not induce Paget disease
    Noriyoshi Kurihara
    VA Pittsburgh Healthcare System, Research and Development, Pittsburgh, Pennsylvania 15240, USA
    J Clin Invest 117:133-42. 2007
    ....
  8. ncbi Differential gene expression in cultured osteoblasts and bone marrow stromal cells from patients with Paget's disease of bone
    Dorit Naot
    Department of Medicine, University of Auckland, New Zealand
    J Bone Miner Res 22:298-309. 2007
    ..We identified several differentially regulated genes, and we suggest that these changes could lead to the formation of the lesions...
  9. ncbi Randomized trial of intensive bisphosphonate treatment versus symptomatic management in Paget's disease of bone
    Anne L Langston
    Rheumatic Diseases Unit, Institute of Genetics and Molecular Medicine University of Edinburgh, United Kingdom
    J Bone Miner Res 25:20-31. 2010
    ..Neither management strategy had a significant beneficial impact on pain or quality of life (Clinical trial registration number ISRCTN12989577)...
  10. ncbi Genome-wide association study identifies variants at CSF1, OPTN and TNFRSF11A as genetic risk factors for Paget's disease of bone
    Omar M E Albagha
    Rheumatic Diseases Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Edinburgh, UK
    Nat Genet 42:520-4. 2010
    ..09 x 10(-13)) and with rs3018362 on 18q21 near the TNFRSF11A gene (P = 5.27 x 10(-13)). These studies provide new insights into the pathogenesis of PDB and identify OPTN, CSF1 and TNFRSF11A as candidate genes for disease susceptibility...
  11. ncbi Enhanced ATPase activities as a primary defect of mutant valosin-containing proteins that cause inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia
    Atsushi Manno
    Laboratory of Functional Biology, Kyoto University Graduate School of Biostudies, Kyoto 606 8501, Japan
    Genes Cells 15:911-22. 2010
    ..Elevated ATPase activities, thus, may be a hidden primary defect causing IBMPFD pathological phenotypes, which would be revealed when abnormal proteins are accumulated, as typically observed in aging...
  12. ncbi Detection of canine distemper virus in 100% of Paget's disease samples by in situ-reverse transcriptase-polymerase chain reaction
    A P Mee
    Bone Disease Research Centre, University Department of Medicine, Manchester Royal Infirmary, UK
    Bone 23:171-5. 1998
    ..These results provide additional proof that CDV is present within pagetic bone and further support the hypothesis that paramyxoviruses are involved in the etiopathology of Paget's disease...
  13. ncbi A comparison of in situ hybridisation, reverse transcriptase-polymerase chain reaction (RT-PCR) and in situ-RT-PCR for the detection of canine distemper virus RNA in Paget's disease
    Judith A Hoyland
    Laboratory Medicine Academic Group, University of Manchester, Stopford Building, Oxford Road, Manchester M13 9PT, UK
    J Virol Methods 109:253-9. 2003
    ..These findings also have wider implications for other studies investigating viral expression...
  14. ncbi Valosin-containing protein disease: inclusion body myopathy with Paget's disease of the bone and fronto-temporal dementia
    Conrad C Weihl
    Department of Neurology, Washington University School of Medicine, Saint Louis, MO 63110, USA
    Neuromuscul Disord 19:308-15. 2009
    ....
  15. ncbi Pathological consequences of VCP mutations on human striated muscle
    Christian U Hübbers
    Institute of Biochemistry I, University of Cologne, Cologne, Germany
    Brain 130:381-93. 2007
    ..The latter findings provide a novel link to VCP carbohydrate interactions in the complex pathology of IBMPFD...
  16. ncbi Paget disease of bone: mapping of two loci at 5q35-qter and 5q31
    N Laurin
    Molecular Endocrinology and Oncology Research Center, CHUL Research Center, Quebec, QC, Canada G1V 4G2
    Am J Hum Genet 69:528-43. 2001
    ..It is proposed that the 5q35-qter and 5q31 loci be named "PDB3" and "PDB4," respectively...
  17. ncbi A randomized clinical trial comparing oral alendronate and intravenous pamidronate for the treatment of Paget's disease of bone
    J P Walsh
    Department of Endocrinology and Diabetes, Sir Charles Gairdner Hospital, Nedlands, WA 6009, Australia
    Bone 34:747-54. 2004
    ..In patients previously treated with pamidronate, alendronate is more effective...
  18. ncbi Role of TAFII-17, a VDR binding protein, in the increased osteoclast formation in Paget's Disease
    Noriyoshi Kurihara
    Department of Medicine/Hematology and Oncology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
    J Bone Miner Res 19:1154-64. 2004
    ..TAFII-17 can bind VDR at low concentrations of 1,25(OH)2D3. These results suggest that MVNP expression in Paget's OCL precursors increases expression of a component(s) of the VDR transcription complex that can increase OCL formation...
  19. ncbi Recalculation of secular trends in Paget's disease
    H A Waldron
    J Bone Miner Res 19:523. 2004
  20. ncbi Analysis of environmental factors in familial versus sporadic Paget's disease of bone--the New England Registry for Paget's Disease of Bone
    Margaret Seton
    Arthritis Unit, New England Registry for Paget s Disease of Bone, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    J Bone Miner Res 18:1519-24. 2003
    ..Those with a family history of PD (20%) suffered earlier deformity and fracture, and tended to have grandparents born abroad. These findings suggest heritage is important in PD; the role of environment remains unclear...
  21. ncbi Effect of age and gender on the number and distribution of sites in Paget's disease of bone
    M J Haddaway
    Department of Diagnostic Imaging, Robert Jones and Agnes Hunt Orthopaedic Hospital, Oswestry, Shropshire SY10 7AG, UK
    Br J Radiol 80:532-6. 2007
    ..The lesser involvement at the axial sites in monostotic disease may lead to overestimation of the decline in PDB based on abdominal radiographs...
  22. ncbi Paget's disease of bone in The Netherlands: a population-based radiological and biochemical survey--the Rotterdam Study
    Marelise E M W Eekhoff
    Department of Endocrinology and Metabolic Diseases, Leiden University Medical Center, Leiden, The Netherlands
    J Bone Miner Res 19:566-70. 2004
    ..This study demonstrated that serum ALP activity is a sensitive marker of PDB in men and women >55 years of age, but the majority of those affected have normal serum ALP activity...
  23. ncbi [Italian guidelines for the diagnosis and treatment of Paget's disease of bone]
    S Adami
    Reumatologia, Universita di Verona, Verona, Italia
    Reumatismo 59:153-68. 2007
    ..The document provides the most updated recommendations based primarily on the "evidence-based- medicine" but also on the Italian regulation for the diagnostic procedures and on the available medical treatments...
  24. ncbi Comparison of different intravenous bisphosphonate regimens for Paget's disease of bone
    Daniela Merlotti
    Department of Internal Medicine, Endocrine, Metabolic Sciences, and Biochemistry, University of Siena, Siena, Italy
    J Bone Miner Res 22:1510-7. 2007
    ..Single neridronate and zoledronate infusion showed a similar efficacy in up to 90% of patients nonresponders to pamidronate...
  25. ncbi Guidelines for the diagnosis and management of Paget's disease: a UK perspective
    Peter L Selby
    University Department of Medicine, Manchester Royal Infirmary, Manchester, United Kingdom
    J Bone Miner Res 21:P92-3. 2006
  26. ncbi Evaluation of the role of Valosin-containing protein in the pathogenesis of familial and sporadic Paget's disease of bone
    Gavin J A Lucas
    Department of Medicine and Therapeutics, University of Aberdeen, UK
    Bone 38:280-5. 2006
    ..Genetic variation in VCP does not appear to be a common cause of familial or sporadic PDB in the absence of myopathy and dementia...
  27. ncbi Prevalence of Paget's disease of bone in Italy
    Luigi Gennari
    Department of Internal Medicine, Endocrine Metabolic Sciences and Biochemistry, University of Siena, Siena, and Department of Radiology, U O A I S Giovanni Battista Hospital of Torino, Italy
    J Bone Miner Res 20:1845-50. 2005
    ..7% to 2.4%, were higher in males than in females, and slightly differed between the two towns. Unlike previous studies in populations of British descent, no secular trend for a decreasing prevalence emerged...
  28. ncbi Evidence for increased clinical severity of familial and sporadic Paget's disease of bone in Campania, southern Italy
    Domenico Rendina
    Department of Clinical and Experimental Medicine, Federico II University Medical School, Naples, Italy
    J Bone Miner Res 21:1828-35. 2006
    ..This peculiar pattern might be traced to genetic predisposition and/or to the abnormal impact of a still undefined environmental trigger...
  29. ncbi Canine distemper virus induces human osteoclastogenesis through NF-kappaB and sequestosome 1/P62 activation
    Peter L Selby
    Vitamin D Research Group, University School of Medicine, Manchester Royal Infirmary, Oxford Road, Manchester, United Kingdom
    J Bone Miner Res 21:1750-6. 2006
    ..We studied the effects of CDV on osteoclastogenesis in vitro and showed that CDV had a dose-dependent effect on osteoclastogenesis, through a possible mechanism involving activation of NF-kappaB and sequestosome 1/p62...
  30. ncbi Characteristics and familial aggregation of Paget's disease of bone in Italy
    Daniela Merlotti
    Department of Internal Medicine, Endocrine Metabolic Sciences and Biochemistry, University of Siena, Siena, Italy
    J Bone Miner Res 20:1356-64. 2005
    ..Familial aggregation was observed in 15% of cases...
  31. ncbi Mechanisms of disease: genetics of Paget's disease of bone and related disorders
    Anna Daroszewska
    University of Edinburgh, UK
    Nat Clin Pract Rheumatol 2:270-7. 2006
    ....
  32. ncbi Severe hypocalcemia following bisphosphonate treatment in a patient with Paget's disease of bone
    Heather E Whitson
    GRECC, VA Medical Center, Durham, NC 27710, USA
    Bone 39:954-8. 2006
    ..Physicians should be aware of the potential for hypocalcemia when patients with polyostotic Paget's disease and markedly elevated indicators of bone remodeling are initiated on powerful anti-resorptive therapy...
  33. ncbi Non-isomerized C-telopeptide fragments are highly sensitive markers for monitoring disease activity and treatment efficacy in Paget's disease of bone
    Peter Alexandersen
    Centre for Clinical and Basic Research, Ballerup, Denmark
    J Bone Miner Res 20:588-95. 2005
    ....
  34. ncbi Multicenter blinded analysis of RT-PCR detection methods for paramyxoviruses in relation to Paget's disease of bone
    Stuart H Ralston
    Rheumatic Diseases Unit, School of Molecular and Clinical Medicine, University of Edinburgh, Edinburgh, UK
    J Bone Miner Res 22:569-77. 2007
    ....
  35. ncbi Genetics of Paget's disease of bone
    Laetitia Michou
    Clinical Genetics Unit, Hopital Lariboisiere, Paris, France
    Joint Bone Spine 73:243-8. 2006
    ..Detection of a mutation allows evaluation of family members to ensure early diagnosis of the disease before complications develop...
  36. ncbi Sequestosome 1: mutation frequencies, haplotypes, and phenotypes in familial Paget's disease of bone
    Jean Morissette
    Centre de recherche en endocrinologie moléculaire et oncologique, Centre de Recherche du Centre Hospitalier de l Universite Laval, Quebec, Quebec, Canada
    J Bone Miner Res 21:P38-44. 2006
    ..The P392L mutation was the most prevalent, embedded in two different haplotypes, possibly shared by other populations. We also examined the phenotype and penetrance of P392L...
  37. ncbi Is the prevalence of Paget's disease of bone decreasing?
    Tim Cundy
    Department of Medicine, University of Auckland, Auckland, New Zealand
    J Bone Miner Res 21:P9-13. 2006
    ..Paget's disease has become less prevalent and patients are presenting later, with less severe disease than previously. These data suggest that environmental factors are important in the etiology of Paget's disease...
  38. ncbi Comparative responses of bone turnover markers to bisphosphonate therapy in Paget's disease of bone
    Ian R Reid
    Department of Medicine, University of Auckland, Private Bag 92019, New Zealand
    Bone 35:224-30. 2004
    ..There is no clear evidence from this study that any of these newer markers are superior to total AP in assessing patients with this severity of Paget's disease...
  39. ncbi Diagnosis and treatment of Paget's disease of bone
    Robert G Josse
    Division of Endocrinology and Metabolism, Department of Medicine, St Michael s Hospital, University of Toronto, Toronto, Ontario
    Clin Invest Med 30:E210-23. 2007
    ..The Panel recommends treating PDB with bisphosphonates that have demonstrated superior efficacy and remission rates...
  40. ncbi Novel SQSTM1 mutations in patients with Paget's disease of bone in an unrelated multiethnic American population
    Laetitia Michou
    Department of Medicine, Laval University, CHUQ CHUL Research centre and Division of Rheumatology, CHUQ CHUL, Quebec City, QC, Canada
    Bone 48:456-60. 2011
    ..The SQSTM1 mutation rate in unrelated American patients described in the present study was similar to that reported in European populations...
  41. ncbi VCP/p97 is essential for maturation of ubiquitin-containing autophagosomes and this function is impaired by mutations that cause IBMPFD
    Emilie Tresse
    Department of Developmental Neurobiology, St Jude Children s Research Hospital, Memphis, TN, USA
    Autophagy 6:217-27. 2010
    ..We conclude that VCP is essential for maturation of ubiquitin-containing autophagosomes and that defect in this function may contribute to IBMPFD pathogenesis...
  42. ncbi Increased circulating Dickkopf-1 in Paget's disease of bone
    Michael J Marshall
    Charles Salt Centre for Human Metabolism, Robert Jones and Agnes Hunt Orthopaedic Hospital NHS Trust, Oswestry, Shropshire, SY10 7AG, UK
    Clin Biochem 42:965-9. 2009
    ..Dkk-1 over-production is implicated in osteolytic disease where it inhibits bone formation and stimulates bone breakdown. Recently it was reported that osteoblastic cells from Paget's disease of bone (PDB) over-expressed Dkk-1...
  43. ncbi Contributions of the measles virus nucleocapsid gene and the SQSTM1/p62(P392L) mutation to Paget's disease
    Noriyoshi Kurihara
    University of Pittsburgh, Medicine Hem Onc, Pittsburgh, PA 15213, USA
    Cell Metab 13:23-34. 2011
    ..Mice coexpressing MVNP and p62(P394L) developed dramatic Paget's-like bone lesions. These results suggest that p62(P394L) and IL-6 induction by MVNP play key roles in PD...
  44. ncbi Paget disease: when to treat and when not to treat
    Frederick R Singer
    John Wayne Cancer Institute at Saint John s Health Center, Santa Monica, CA 90404, USA
    Nat Rev Rheumatol 5:483-9. 2009
    ..Future studies are needed to determine whether these drugs, if used in an early stage of the disease, can prevent complications in asymptomatic patients...
  45. ncbi Linkage of Paget disease of bone to a novel region on human chromosome 18q23
    David A Good
    Department of Diabetes and Endocrinology, Princess Alexandra Hospital, Brisbane, Australia
    Am J Hum Genet 70:517-25. 2002
    ..71, at marker D18S70. Our data are consistent with genetic heterogeneity within the pedigree and indicate that 18q23 harbors a novel susceptibility gene for PDB...
  46. ncbi Usefulness of biochemical markers of bone turnover in assessing response to the treatment of Paget's disease
    L Alvarez
    Service of Clinical Biochemistry, Hospital Clinic, University of Barcelona, Barcelona, Spain
    Bone 29:447-52. 2001
    ..Data on biological variation are useful for assessing actual changes induced by treatment...
  47. ncbi Gene expression profile in osteoclasts from patients with Paget's disease of bone
    Laetitia Michou
    Department of Medicine, Laval University, Canada G1V 4G2
    Bone 46:598-603. 2010
    ..They also suggest that the SQSTM1 P392L mutation plays a role in PDB pathogenesis, even at early preclinical stages in healthy carriers of the P392L mutation...
  48. ncbi Mutation screening of the TNFRSF11A gene encoding receptor activator of NF kappa B (RANK) in familial and sporadic Paget's disease of bone and osteosarcoma
    A B Sparks
    Molecular Genetics Laboratory, Johns Hopkins Oncology Center, Baltimore, MD, USA
    Calcif Tissue Int 68:151-5. 2001
    ..These data indicate that TNFRSF11A mutations contribute neither to the vast majority of cases of sporadic or familial PDB, nor to the development of osteosarcoma...
  49. ncbi Circulating and tissue-derived isoforms of bone alkaline phosphatase in Paget's disease of bone
    Per Magnusson
    Bone and Mineral Metabolic Unit, Division of Clinical Chemistry, Department of Clinical and Experimental Medicine, Faculty of Health Sciences at Linköping University, Linkoping, Sweden
    Scand J Clin Lab Invest 70:128-35. 2010
    ..Alkaline phosphatase (ALP) is routinely used in the assessment of Paget's disease of bone (PDB); however, the individual bone ALP isoforms (B/I, B1, and B2) have not been investigated in this disorder...
  50. ncbi Improvement of pagetic bone lesions with risedronate treatment: a radiologic study
    J P Brown
    Le Centre Hospitalier Universitaire de Quebec, Sainte Foy, Canada
    Bone 26:263-7. 2000
    ..Risedronate treatment had no deleterious effect on osteolytic lesions in weight-bearing bones; indeed, the majority of lesions with osteolytic fronts were improved after 6 months of risedronate treatment...
  51. ncbi Insights into the pathogenesis of Paget's disease
    G David Roodman
    University of Pittsburgh, School of Medicine Hematology Oncology, Pittsburgh, PA, USA
    Ann N Y Acad Sci 1192:176-80. 2010
    ..These studies suggest that both genetic and environmental factors contribute to PD...
  52. ncbi Paget's disease of bone is not associated with common polymorphisms in interleukin-6, interleukin-8 and tumor necrosis factor alpha genes
    Luis Corral-Gudino
    Servicio de Medicina Interna, RETICEF, Hospital Universitario de Salamanca, Los Montalvos s n, Salamanca, Spain
    Cytokine 52:146-50. 2010
    ..Cytokines, specially interleukin (IL)-6, play an important role in the differentiation and activation of osteoclasts and might be involved in osteoblast stimulation in Paget's disease of bone (PDB)...
  53. ncbi The majority of the genetic risk for Paget's disease of bone is explained by genetic variants close to the CSF1, OPTN, TM7SF4, and TNFRSF11A genes
    Pui Yan Jenny Chung
    Department of Medical Genetics, University and University Hospital of Antwerp, 2610, Antwerp, Belgium
    Hum Genet 128:615-26. 2010
    ..The calculated cumulative population attributable risk of these four loci turned out to be about 67% in our two populations, indicating that most of the genetic risk for PDB is coming from genetic variants close to these four genes...
  54. ncbi Genetic linkage of familial expansile osteolysis to chromosome 18q
    A E Hughes
    Department of Medical Genetics, Queen s University of Belfast, UK
    Hum Mol Genet 3:359-61. 1994
    ..1-q22. Mapping a new locus for a gene involved in regulation of bone metabolism may also have implications in the study of Paget's disease of bone which is a common related bone dysplasia...
  55. ncbi Paget's disease of bone: the skeletal distribution, complications and quality of life as perceived by patients
    M Seton
    Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Bulfinch 165, 55 Fruit Street, Boston, MA 02114, USA
    Bone 48:281-5. 2011
    ..Paget's disease of bone (PDB) is a focal disorder of bone metabolism with overgrowth of affected bone resulting in the skeletal complications of this disease...
  56. ncbi Paget's disease in an archeological population
    J Rogers
    Department of Rheumatology, Bristol Royal Infirmary, United Kingdom
    J Bone Miner Res 17:1127-34. 2002
    ..This is likely caused by the small sample size, but this is by far the greatest number of cases of PDB described in a single skeletal assemblage to date. The distribution of lesions within the skeleton is unchanged...
  57. ncbi Pathogenesis of Paget's disease of bone
    Stuart H Ralston
    Rheumatic Diseases Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh EH4 2XU, UK
    Bone 43:819-25. 2008
    ....
  58. ncbi Morbidity and mortality associated with Paget's disease of bone: a population-based study
    Robert A Wermers
    Division of Endocrinology, Metabolism and Nutrition, Department of Internal Medicine, College of Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    J Bone Miner Res 23:819-25. 2008
    ..We examined morbidity and mortality associated with this condition in a large inception cohort of Olmsted County, MN, residents with a new diagnosis of Paget's disease from 1950 through 1994...
  59. ncbi Management of patients with Paget's disease: a consensus document of the Belgian Bone Club
    J P Devogelaer
    Service de Rhumatologie, Cliniques Universitaires Saint Luc, Universite Catholique de Louvain, Avenue Hippocrate 10, 1200 Brussels, Belgium
    Osteoporos Int 19:1109-17. 2008
    ..Its therapeutic efficacy, its long-term effect on biologic activity and its good tolerance currently supports its use as a first-line therapeutic option in patients suffering from PDB...
  60. ncbi Gene expression profiling in Paget's disease of bone: upregulation of interferon signaling pathways in pagetic monocytes and lymphocytes
    Zsolt B Nagy
    National Institute of Rheumatology and Physiotherapy, Budapest, Hungary
    J Bone Miner Res 23:253-9. 2008
    ..We found a significant overexpression of the genes of the IFN pathway along with a downregulation of tnf-alpha. Our result suggest that IFN-mediated signaling may play important roles in aberrant osteoclastogenesis of PD...
  61. ncbi A SQSTM1/p62 mutation linked to Paget's disease increases the osteoclastogenic potential of the bone microenvironment
    Yuko Hiruma
    Department of Medicine Hematology Oncology, University of Pittsburgh Medical Center, Pittsburgh, PA 15240, USA
    Hum Mol Genet 17:3708-19. 2008
    ..These results indicate that this PDB-associated p62 mutation is not sufficient to induce PDB and suggest that additional factors acting together with p62 mutation are necessary for the development of PDB in vivo...
  62. ncbi Randomized, active-controlled study of once-weekly alendronate 280 mg high dose oral buffered solution for treatment of Paget's disease
    M Hooper
    University of Sydney, 56 St Johns Ave, Gordon, NSW, 2072, Australia
    Osteoporos Int 20:141-50. 2009
    ..A once-weekly alendronate 280 mg oral buffered solution was compared with an alendronate 40 mg/day tablet. While both were similarly effective, the tablet appeared to be better tolerated in this study...
  63. ncbi Juvenile Paget's disease: the second reported, oldest patient is homozygous for the TNFRSF11B "Balkan" mutation (966_969delTGACinsCTT), which elevates circulating immunoreactive osteoprotegerin levels
    Michael P Whyte
    Center for Metabolic Bone Disease and Molecular Research, Shriners Hospitals for Children, St Louis, Missouri 63131, USA
    J Bone Miner Res 22:938-46. 2007
    ..Elevated circulating levels of immunoreactive OPG and soluble RANKL accompany this genetic defect that truncates the OPG monomer, preventing formation of OPG homodimers...
  64. ncbi A review of Paget's disease of bone with a focus on the efficacy and safety of zoledronic acid 5 mg
    Abby Abelson
    Center for Osteoporosis and Metabolic Bone Disease, Department of Rheumatic and Immunologic Diseases, Orthopaedic and Rheumatology Institute, The Cleveland Clinic, Cleveland, OH 44195, USA
    Curr Med Res Opin 24:695-705. 2008
    ..The objective of this review is to provide a comprehensive overview of current standards of treatment in Paget's disease...
  65. ncbi The molecular pathogenesis of Paget disease of bone
    Robert Layfield
    School of Biomedical Sciences, University of Nottingham Medical School, Nottingham, NG7 2UH, UK
    Expert Rev Mol Med 9:1-13. 2007
    ....
  66. ncbi [Diagnosis and management of Paget's disease of bone]
    Jun Hashimoto
    Department of Orthopaedics, Osaka University Graduate School of Medicine
    Nippon Rinsho 65:56-64. 2007
  67. ncbi Serum OPG and RANKL levels before and after intravenous bisphosphonate treatment in Paget's disease of bone
    G Martini
    Department of Internal Medicine, Endocrine Metabolic Sciences and Biochemistry, University of Siena, Policlinico Le Scotte, Viale Bracci 1, 53100 Siena, Italy
    Bone 40:457-63. 2007
    ..Thus, the positive effect of amino bisphosphonates in the treatment of PDB may be due to either direct or indirect suppression of RANKL-induced bone resorption through decreased RANKL and increased OPG production...
  68. ncbi [Therapy of Paget's disease]
    A A Kurth
    Orthopadische Universitatsklinik, Stiftung Friedrichsheim, Marienburgstrasse 2, 60528 Frankfurt
    Orthopade 36:118, 120-3. 2007
    ..The article gives an overview of recent perspectives on epidemiology, diagnosis, and treatment of the disease according to the new German guidelines for the diagnosis and therapy of Paget's disease...
  69. ncbi Biochemical response to bisphosphonate therapy in pagetic patients with skull involvement
    P Peris
    Department of Rheumatology, Hospital Clinic, University of Barcelona, Institut d Investigacions Biomediques August Pi i Sunyer IDIBAPS, Barcelona, Spain
    Calcif Tissue Int 79:22-6. 2006
    ..In conclusion, pagetic patients with skull involvement showed a marked increase in bone turnover and a lower response to therapy...
  70. ncbi [Paget disease of bone]
    Kyoji Okada
    Department of Orthopedic Surgery, Akita University School of Medicine
    Nippon Rinsho . 2006
  71. ncbi Implications of bisphosphonate use for the dentist: an introduction
    Gregori M Kurtzman
    Dent Today 25:80, 82-5; quiz 85. 2006
  72. ncbi Long-term control of bone turnover in Paget's disease with zoledronic acid and risedronate
    David Hosking
    City Hospital, Nottingham, UK
    J Bone Miner Res 22:142-8. 2007
    ..This effect is largely independent of pretreatment disease activity and prior bisphosphonate therapy...
  73. ncbi Paget's disease of the bone: a report of three cases
    K Bhatt
    Rheumatology Division, PD Hinduja Hospital and MRC, Veer Savarkar Marg, Mumbai
    J Assoc Physicians India 54:571-4. 2006
    ..All three had elevated markers of bone metabolism in the serum and urine. With monthly intravenous pamidronate there was significant improvement in the bone markers and follow-up bone scans...
  74. ncbi [Osteitis deformans (Osteodystrophia deformans)--Pagent disease of bone. Leading symptoms: bone pain, bone deformities, fractures]
    F Marti
    Medizinische Poliklinik,
    Praxis (Bern 1994) 96:359-65; quiz 366-7. 2007
  75. ncbi Multiple fractures in a woman receiving 24 years of etidronate treatment for Paget's disease
    Paul Labinson
    University of Connecticut School of Medicine, Division of Endocrinology and Metabolism, Farmington, USA
    Conn Med 71:269-73. 2007
  76. ncbi Treatment with tiludronate has a similar effect to risedronate on Paget's disease activity assessed by bone markers and bone scintigraphy
    P Peris
    Services of Rheumatology, Hospital Clinic, University of Barcelona, Institut d Investigacions Biomediques August Pi i Sunyer IDIBAPS, Barcelona, Spain
    Clin Exp Rheumatol 25:206-10. 2007
    ..To compare the effects of tiludronate and risedronate on Paget's disease activity assessed by biochemical markers of bone turnover and quantitative bone scintigraphy...
  77. ncbi Familial expansile osteolysis (excessive RANK effect) in a 5-generation American kindred
    Michael P Whyte
    Center for Metabolic Bone Disease and Molecular Research, Shriners Hospitals for Children, St. Louis, Missouri 63131, USA
    Medicine (Baltimore) 81:101-21. 2002
  78. ncbi Bisphosphonates: mechanism of action and role in clinical practice
    Matthew T Drake
    Division of Endocrinology, Diabetes, Metabolism, and Nutrition, Mayo Clinic, Rochester, MN 55905, USA
    Mayo Clin Proc 83:1032-45. 2008
    ....
  79. ncbi Bisphosphonate treatment increases the size of the mandibular condyle and normalizes growth of the mandibular ramus in osteoprotegerin-deficient mice
    Masakazu Kimura
    Department of Orthodontics, School of Dentistry, Aichi Gakuin University, Chikusa ku, Nagoya 464 8651, Japan
    Calcif Tissue Int 82:137-47. 2008
    ..In conclusion, bisphosphonate treatment results in an increase in mandibular condylar dimensions and normalization of mandibular ramus growth...
  80. ncbi Pathogenesis and management of Paget's disease of bone
    Stuart H Ralston
    Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK
    Lancet 372:155-63. 2008
    ..No firm evidence as yet exists to show that bisphosphonates can prevent the development of complications of Paget's disease of bone, and further work is needed to address the effects of treatment on long-term clinical outcome...
  81. ncbi Osteonecrosis of the jaw and bisphosphonates--putting the risk in perspective
    Mark Bolland
    Department of Medicine, University of Auckland
    N Z Med J 119:U2339. 2006
    ..The aim of this article is to put the risks of osteonecrosis of the jaw into context with the benefits of bisphosphonate treatment in these clinical scenarios...
  82. ncbi Medical management of Paget's disease of bone: indications for treatment and review of current therapies
    Ethel S Siris
    Department of Medicine, Columbia University Medical Center, New York Presbyterian Hospital, New York, New York, USA
    J Bone Miner Res 21:P94-8. 2006
    ..It is not known whether resistance to other bisphosphonates in Paget's disease occurs...
  83. ncbi Biochemical markers of bone turnover in the clinical development of drugs for osteoporosis and metastatic bone disease: potential uses and pitfalls
    Serge Cremers
    Department of Medicine, Endocrinology, Columbia University, New York, NY, USA
    Drugs 66:2031-58. 2006
    ..Correctly manipulating these may improve clinical development of drugs for the treatment of patients with metabolic bone diseases such as osteoporosis and cancer metastatic to the bone...
  84. ncbi Persistent effect of zoledronic acid in Paget's disease
    K Tziomalos
    2nd Propedeutic Department of Internal Medicine, Aristotle University of Thessaloniki, Hippokration Hospital, Thessaloniki, Greece
    Clin Exp Rheumatol 25:464-6. 2007
    ..In conclusion, zoledronic acid, apart from being safe and effective in Paget's disease, also appears to be able to achieve significantly prolonged remissions...
  85. ncbi Clinical determinants of quality of life in Paget's disease of bone
    A L Langston
    Health Services Research Unit, University of Aberdeen, Aberdeen, AB25 22D, United Kingdom
    Calcif Tissue Int 80:1-9. 2007
    ..The lack of correlation between ALP and quality of life observed in this study emphasizes the importance of addressing quality-of-life issues when treating PDB and not just focussing on response of ALP levels...
  86. ncbi Investigation of bone disease using isomerized and racemized fragments of type I collagen
    P A C Cloos
    Nordic Bioscience A S, Herlev Hovedgade 207, DK 2730 Herlev, Denmark
    Calcif Tissue Int 72:8-17. 2003
    ..This may provide a new diagnostic and monitoring tool for diseases such as metastatic bone cancer and Paget's disease...
  87. ncbi [Development of bisphosphonates]
    Kiyoshi Nakatsuka
    Department of Endocrinology, Metabolism, and Molecular Medicine, Osaka City University Graduate School of Medicine
    Nippon Rinsho 61:219-25. 2003
    ....
  88. ncbi Bisphosphonate space measurement and dosage requirement for intravenous clodronate treatment of Paget's disease
    M Rutland
    Department of Nuclear Medicine, Auckland Hospital, Auckland, New Zealand
    Calcif Tissue Int 70:99-102. 2002
    ..Both ALP and the bisphosphonate space have wide prediction intervals, and are therefore poor guides to dose requirement...
  89. ncbi Long-term biochemical response after bisphosphonate therapy in Paget's disease of bone. Proposed intervals for monitoring treatment
    L Alvarez
    Servicio Bioquimica Clinica, Hospital Clinic, C Villarroel 170, 08036 Barcelona, Spain
    Rheumatology (Oxford) 43:869-74. 2004
    ....
  90. ncbi Treatment of idiopathic hyperphosphatasia with intensive bisphosphonate therapy
    Tim Cundy
    Department of Medicine, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand
    J Bone Miner Res 19:703-11. 2004
    ..Their youngest affected sibling was treated intensively with intravenous bisphosphonates for 3 years. The treatment was well tolerated and prevented the development of deformity and disability...
  91. ncbi Intravenously administered pamidronate in the treatment of Paget's disease of bone
    J R Tucci
    Division of Endocrinology, Department of Medicine, Roger Williams Hospital, 825 Chalkstone Avenue, Providence, RI 02908, USA
    Endocr Pract 7:423-9. 2001
    ....
  92. ncbi Risedronate and pamidronate treatment in the clinical management of patients with severe Paget's disease of bone and acquired resistance to bisphosphonates
    D Rendina
    Department of Clinical and Experimental Medicine, Federico II University Medical School, 80131 Naples, Italy
    Calcif Tissue Int 75:189-96. 2004
    ..In patients with resistant PDB, oral risedronate therapy has comparable efficacy to IV pamidronate with a lower incidence of treatment-related side effects...
  93. ncbi Immunohistochemical localization of the prostacyclin receptor (IP) human bone
    I Fortier
    Rheumatic Diseases Unit, Department of Medicine, Faculte de Medecine, Universite de Sherbrooke, Sherbrooke, Canada
    Prostaglandins Leukot Essent Fatty Acids 65:79-83. 2001
    ....
  94. ncbi Studies in Paget's disease and their relevance to oncology
    G D Roodman
    Department of Medicine/Hematology, University of Texas Health Science Center, San Antonio, TX, USA
    Semin Oncol 28:15-21. 2001
    ..Paget's disease provides an ideal model in which to investigate the efficacy of the new third-generation bisphosphonates in the treatment of bone metastases as well as nonmalignant bone disease...
  95. ncbi Management of Paget's disease of bone
    A L Langston
    Health Services Research Unit, University of Aberdeen, UK
    Rheumatology (Oxford) 43:955-9. 2004
    ....
  96. ncbi Two cases of monostotic Paget's disease: effects of bisphosphonate
    Madoka Hoshiro
    Department of Endocrinology, Metabolism and Diabetes Mellitus, Kinki University School of Medicine, Osaka-Sayama 589-8511, Japan
    Endocr J 50:385-92. 2003
    ..When she died of colon cancer twelve months later, with no marked progress of the Paget's disease of bone observed clinically...
  97. ncbi Effect of bisphosphonate treatment in patients with Paget's disease of the skull
    J Donath
    National Institute of Rheumatology and Physiotherapy, Budapest, Hungary
    Rheumatology (Oxford) 43:89-94. 2004
    ..Hearing loss has long been known to be a complication of Paget's disease of bone. The aim of this study was to investigate Paget's disease of the temporal bone with special attention to hearing loss...
  98. ncbi Short-term intravenous therapy with Neridronate in Paget's disease
    S Adami
    Department of Rheumatology, Valeggio S M, University of Verona, Italy
    Clin Exp Rheumatol 20:55-8. 2002
    ..To describe the effects of two consecutive intravenous infusions of aminohexane bisphosphonate (Neridronate) in patients with active Paget's disease of bone...
  99. ncbi Paget's disease of bone: presentation, extent and response to bisphosphonates
    L M Wang
    St. Michael's Hospital, , Co. Dublin
    Ir Med J 95:244, 246. 2002
    ..Complications were common including deformity (21%), fracture (17%) and deafness (8%). Bisphosphonate therapy induced a remission in 22 patients...
  100. ncbi Magnetic resonance imaging presentation of lytic Paget's disease of the cervical spine
    Stanley Sprecher
    Peninsula Hospital Center, Department of Imaging Services, Far Rockaway, New York 11691, USA
    J Bone Miner Res 17:1929-30. 2002
  101. ncbi Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats
    Pierrick Fournier
    , Research Unit 403, , Lyon 69372, France
    Cancer Res 62:6538-44. 2002
    ..In addition, our results extend the potential clinical use of BPs to patients with early prostate cancer...

Research Grants84

  1. CLONING NOVEL GENES FOR PAGETS DISEASE AND OSTEOSARCOMA
    Marc Hansen; Fiscal Year: 2001
    DESCRIPTION (Adapted from the Applicant's Abstract): Paget's disease of bone, or osteitis deformans, is a bone disorder characterized by rapid bone remodeling, resulting in abnormal bone formation...
  2. TWO X-LINKED GENES THAT REGULATE MINERAL HOMEOSTASIS
    Michael Whyte; Fiscal Year: 2002
    ....
  3. AAA ATPase p97/VCP and Inclusion Body Myopathy
    CONRAD WEIHL; Fiscal Year: 2007
    ..These studies will lend insight into the molecular and cellular mechanisms involved in IBM disease pathogenesis and are critical for identifying future therapeutic targets. ..
  4. IBMPFD MUTATIONS IMPAIR UPS FUNCTION
    Conrad C Weihl; Fiscal Year: 2010
    ..We propose to explore the consequence of disease mutations in p97/VCP on UPS-mediated protein degradation in skeletal muscle and its relevance to aging related disorders such as inclusion body myositis and fronto-temporal dementia. ..
  5. IBMPFD MUTATIONS IMPAIR UPS FUNCTION
    CONRAD WEIHL; Fiscal Year: 2009
    ..We propose to explore the consequence of disease mutations in p97/VCP on UPS-mediated protein degradation in skeletal muscle and its relevance to aging related disorders such as inclusion body myositis and fronto-temporal dementia. ..
  6. IBMPFD MUTATIONS IMPAIR UPS FUNCTION
    CONRAD WEIHL; Fiscal Year: 2009
    ..We propose to explore the consequence of disease mutations in p97/VCP on UPS-mediated protein degradation in skeletal muscle and its relevance to aging related disorders such as inclusion body myositis and fronto-temporal dementia. ..
  7. INHIBITION OF OSTEOCLAST ACTIVITY BY OIP1/HSCAL
    SAKAMURI REDDY; Fiscal Year: 2002
    ....
  8. GENE CAUSING PAGET & LIMB-GIRDLE MUSCULAR DYSTROPHY
    Virginia Kimonis; Fiscal Year: 2003
    ..Delineation of the genetic component responsible for the LGMD/PDB phenotype should promise similar insight and facilitate in the design of novel treatment protocols for the two disorders. ..
  9. Genetic basis of myopathy with Paget disease of bone
    Virginia Kimonis; Fiscal Year: 2007
    ..e. effect on ATPase activity, protein-protein interactions, and hexamer formation). Study the VCP specific pathways in C2C12 cell lines (stably transfected wt and R155H VCP) during differentiation and under stress conditions...
  10. Characterization of Familial Myopathy & Paget Disease
    Virginia Kimonis; Fiscal Year: 2005
    ..Elucidation of the genetic defect will help us understand the pathogenesis of this multifaceted disorder and hopefully result in specific therapy. ..
  11. INHIBITION OF OSTEOCLAST ACTIVITY BY OIP-1/HSCAL
    SAKAMURI REDDY; Fiscal Year: 2007
    ..abstract_text> ..
  12. METABOLISM IN NORMAL AND OSTEOARTHRITIC CARTILAGE
    Henry Mankin; Fiscal Year: 1991
    ..The receptors for this cytokine on normal and OA chondrocytes will be quantitated. Further definition of these cartilage metabolic pathways are of primary importance in our understanding of osteoarthritis...
  13. Prevention of Postmenopausal Bone Loss with Nitric Oxide
    Sunil Wimalawansa; Fiscal Year: 2007
    ..The study will also pave the way for the future, for providing more acceptable, affordable and cost- effective therapies for the prevention of postmenopausalosteoporosis. ..
  14. FACTORS INFLUENCING BONE METABOLISM
    Lawrence Raisz; Fiscal Year: 1993
    ..We will attempt to find markers for bone resorption using in vitro models, which can then be used to assess resorption in vivo...
  15. MVNP, p62P392L and IL-6 in the Pathogenesis of PD
    G Roodman; Fiscal Year: 2009
    ....
  16. Mechanisms of Tau-Based Neurodegeneration
    Mark Forman; Fiscal Year: 2005
    ..This proposal will also facilitate my transition from a trainee to a fully independent experimental neuropathologist. ..
  17. PATHOBIOLOGY OF THE OSTEOCLAST IN PAGETS DISEASE
    G Roodman; Fiscal Year: 2001
    ....
  18. PATHOBIOLOGY OF THE OSTEOCLAST IN PAGETS DISEASE
    G Roodman; Fiscal Year: 2002
    ..abstract_text> ..
  19. FACTORS INFLUENCING BONE METABOLISM
    Lawrence Raisz; Fiscal Year: 2002
    ....
  20. Remodeling Extracellular Matrix:Degradation of Collagen
    Stephen Krane; Fiscal Year: 2007
    ..We will analyze the skeletal and extraskeletal phenotype of mice with a null mutation in the "neutrophil" collagenase, MMP-8, another collagenase expressed in the skeleton, as well as mice with double null MMP-8/MMP-13. ..
  21. REMODELING EXTRACELLULAR MATRIX--DEGRADATION OF COLLAGEN
    Stephen Krane; Fiscal Year: 2002
    ..Specific Aim 3: Target mutations that encode collagenase resistance into the murine type II collagen (Col2a-1) gene. ..
  22. OSTEOCLASTS FROM TRANSGENIC MICE
    G Roodman; Fiscal Year: 2007
    ..Our long-term goal will be to characterize the role of ADAM8/a9b1 in the bone destruction which accompanies collagen induced arthritis, which will be started in grant year 5. ..
  23. DEVELOPMENTAL ASPECTS OF OSTEOCLAST FORMATION IN VITRO
    G Roodman; Fiscal Year: 2000
    ....
  24. Paget's Disease of Bone/Dysplasia:Advances/Challenges
    G Roodman; Fiscal Year: 2006
    ..to become aware of the effectiveness of the various drugs that can be used to treat the two disorders; 5.) to understand the role of surgery in managing the two disorders. ..
  25. MVNP, p62P392L and IL-6 in the Pathogenesis of PD
    G Roodman; Fiscal Year: 2009
    ..As part of these experiments, we will treat normal human OCL precursors transfected with p62P392L with varying concentrations of IL-6 to determine if they form OCLs that express a complete pagetic phenotype...
  26. DEVELOPMENTAL ASPECTS OF OSTEOCLAST FORMATION IN VITRO
    G Roodman; Fiscal Year: 2005
    ....
  27. OSTEOCLASTS FROM TRANSGENIC MICE
    G Roodman; Fiscal Year: 2003
    ..abstract_text> ..
  28. Program Project Grant-Pathobiology of Paget's Disease
    G Roodman; Fiscal Year: 2007
    ..The knowledge gained from this P01 grant will offer important insights for normal bone cell biology especially for understanding the paracrine regulation of osteoblasts by OCLs. ..
  29. OSTEOCLASTS FROM TRANSGENIC MICE
    G Roodman; Fiscal Year: 2009
    ..Our long-term goal will be to characterize the role of ADAM8/a9b1 in the bone destruction which accompanies collagen induced arthritis, which will be started in grant year 5. ..